Background:
Tb is an interesting radionuclide for cancer treatment, showing similar decay characteristics and chemical behavior to clinically-employed 177 Lu. The therapeutic effect of 161 Tb, however, may be enhanced due to the coemission of a larger number of conversion and Auger electrons as compared to 177 Lu. The aim of this study was to produce 161 Tb from enriched 160 Gd targets in quantity and quality sufficient for first application in patients.
Methods: No-carrier-added 161 Tb was produced by neutron irradiation of enriched 160 Gd targets at nuclear research reactors. The Tb. The final product was obtained at an activity concentration of 11-21 MBq/μL with ≥99% radionuclidic and radiochemical purity. The DOTA chelator was radiolabeled with 161 Tb or 177 Lu at the molar activity deemed useful for clinical application, even at the two-week time point after end of chemical separation. DOTATOC, radiolabeled with either 161 Tb or 177 Lu, was stable over 24 h in the presence of a stabilizer.
Conclusions:
In this study, it was shown that 161 Tb can be produced in high activities using different irradiation facilities. The developed method for 161 Tb separation from the target material yielded 161 TbCl 3 in quality suitable for high-specific radiolabeling, relevant for future clinical application.
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Background
The use of the β − -emitter 177 Lu (E β-av = 134 keV (100%), T 1/2 = 6.7 d) (Solá 2000) , in combination with somatostatin analogues (e.g. DOTATOC, DOTATATE), is considered a promising tool for the treatment of neuroendocrine tumors (NET). It has been extensively utilized in clinics, which recently resulted in the approval of Lutathera® ( 177 Lu-DOTATATE), by the U.S. Food and Drug Administration (FDA) (Kam 2012; CHMP 2016) . Treatment with 177 Lu-DOTATATE resulted in longer progression-free survival time (65.2% at Month 20, compared to 10.8% in the control group); nevertheless, partial remission remained at ≤50% in the assessable patients, with the complete response being ≤12% (CHMP 2016; Strosberg 2017; Kwekkeboom 2005; van Essen 2007; Sansovini 2013) .
The radiolanthanide 161
Tb shows similar decay characteristics (E β-av = 154 keV (100%), T 1/2 = 6.9 d (Solá 2000) ) and coordination chemistry to 177 Lu.
161
Tb can, therefore, be stably coordinated with a DOTA chelator and be used in combination with a number of small molecules, peptides and antibodies currently employed with Lu-folate. In a preliminary therapy study using 161 Tb-PSMA-617, PSMA-positive PC-3 PIP tumor-bearing mice demonstrated significant tumor-growth delay, as compared to the control group, without causing early side effects (Müller 2018a) . Better therapeutic efficacy was also observed for a 161 Tb-labeled radioimmunoconjugate in an ovarian cancer model when compared to the 177 Lu-radioimmunoconjugate counterpart (Grünberg 2014) . The low-energy conversion and Auger electron emission from 161 Tb contribute 26% -88% to the total absorbed dose (compared to 10% -34% for 177 Lu), depending on the tumor size, which could be associated to its enhanced therapeutic efficacy over that of 177 Lu (Champion 2016 Lu to 10 mm-diameter spheres were calculated to be comparable for both radionuclides, however, for 100 μm-diameter and 10 μm-diameter spheres 161 Tb could deliver 1.8 and 3.6 times higher dose than 177 Lu, respectively, making 161 Tb the more appropriate candidate for treating micrometastases (Hindie 2016) . Also, the co-emission of 48.9 keV and 74.6 keV 161 Tb γ-rays allows for the acquisition of single photon emission computed tomography (SPECT) images for dosimetry determination before administration of the therapeutic dose, comparable to that performed with 177 Lu (Marin 2018 Tb (SPECT) as a matched pair towards the concept of theragnostics (Müller 2012; Müller 2018b ). Gracheva et al. EJNMMI Radiopharmacy and Chemistry (2019) ). The mass of the target material, required for the irradiation at the chosen facility, was calculated using the ChainSolver code (Romanov 2005 ampoules which stem from traces of cobalt impurities in the used quartz. Based on these 60 Co activity values, the average neutron flux (ϕ th ) of each irradiation was calculated (Table 1 ) using the following equation:
where A 0 is the 60 Co activity at the end of bombardment, σ n the thermal neutron capture cross section (37.18 ± 0.06 b (Mughabghab 2018) ), N the number of target atoms, λ the radioactive decay constant and t B the irradiation time.
Development of the procedure for the 161 Tb purification process A chromatographic column (10 mm × 170 mm) was prepared using Sykam macroporous cation exchange resin (Sykam Chromatographie Vertriebs GmbH, Germany; particle size 12-22 μm, NH 4 + form). The separation parameters were first optimized by means of bench experiments with the use of radioactive tracers (Additional file 1: Table  S2 ) and subsequently applied towards the separation of an aliquot of reactor-produced 161 Tb (230 MBq). These experiments resulted in the design and construction of a chemical separation module, such that high activities (GBq) of the radionuclide can be processed in the hot cell. The quartz glass ampoule with the 160 Gd 2 O 3 target material, delivered from the irradiation facility, was placed in a plastic target tube, crushed and attached to the module inside the hot cell with the aid of manipulators. The target material from the ampoule was dissolved in 2.0 mL 7.0 M nitric acid (HNO 3 , Suprapur, Merck, Germany), followed by evaporation at 80°C under nitrogen flow. The residue was taken up in 0.1 M ammonium nitrate (prepared from 25% Suprapur NH 3 and 65% Suprapur HNO 3 , Merck, Germany) and loaded onto the cation exchange resin column. The 161 Tb separation from the target material and impurities was performed with the use of 0.13 M (pH 4.5) α-hydroxy-isobutyric acid (α-HIBA, Sigma-Aldrich GmbH, Germany) as eluent. Concentration of 161 Tb was performed using the bis(2,4,4-trimethyl-1-pentyl) phosphinic acid extraction resin (LN3, Triskem International, France; 6 mm × 5 mm), followed by the elution of the final product ( 161 TbCl 3 ) in 500 μL 0.05 M hydrochloric acid (HCl, Suprapur, Merck, Germany). The pH of the final product was determined using pH indicator strips (Merck, Germany). Characterization of the 161 Tb product after purification
Radionuclidic purity
The identification and radionuclidic purity of the 161 Tb were examined by γ-ray spectrometry using the HPGe detector mentioned above. The aliquot of the final product, containing 5-10 MBq of 161 Tb, was measured with the HPGe detector until the 3σ uncertainty was below 5%.
Radiochemical purity
The radiochemical purity of the final product was determined by means of radio thin layer chromatography (radio TLC) using a procedure established for 177 Lu (Oliveira 2011 ). The aliquot of 161 TbCl 3 (2 μL,~100 kBq) was deposited on TLC silica gel 60 F 254 plates (Merck, Italy) and placed in the chamber with 0.1 M sodium citrate solution (pH 5.5; Merck, Germany) mobile phase. After elution, the plate was dried and analyzed using a radio TLC scanner instrument (Raytest Isotopenmessgeräte GmbH, Germany).
The results were interpreted with the MiniGita Control software package (version 1.14, Raytest Isotopenmessgeräte GmbH, Germany).
Radiolabeling yield
Radiolabeling of DOTANOC (ABX GmbH, Germany) at a molar activity of 180 MBq/ nmol (1-to-4 nuclide-to-peptide molar ratio) was performed in order to evaluate the success of the purification process. Sodium acetate (Alfa Aesar, Germany; 0.5 M, pH 8) was added to 161 TbCl 3 solution (~200 MBq) to adjust pH to~4.5. The relevant quantity of DOTANOC was subsequently added from a 1 mM stock solution. The reaction solution was incubated for 10 min at 95°C. The radiolabeling yield was determined by reversephase high performance liquid chromatography (HPLC, Merck Hitachi LaChrom) with a radioactivity detector (LB 506, Berthold, Germany) and a C-18 reverse-phase column (150 mm × 4.6 mm; Xterra™ MS, C18; Waters). Trifluoroacetic acid 0.1% (Sigma-Aldrich, USA) in MilliQ water (A) and acetonitrile (VWR Chemicals, USA; HPLC grade) (B) were used as mobile phase with a linear gradient of solvent A (95-5% over 15 min) in solvent B at a flow rate of 1 mL/min. The sample for the analysis was prepared by diluting~0.3 MBq aliquot of the radiolabeling solution in 100 μL MilliQ water containing sodium diethylenetriamine pentaacetic acid (Na-DTPA, 50 μM). The radiolabeling yield of 161 Tb-DOTANOC was determined by integration of the product peak from the obtained HPLC chromatogram in relation to the sum of all radioactive peaks (the radiolabeled product, potentially released 161 Tb as well as degradation products of unknown structure), which were set to 100%. Tb-DOTA at different DOTA-tonuclide molar ratios over time (2 weeks after EOS) and to compare it with the molar activity of 177 Lu-DOTA, thin layer chromatography (TLC) analysis was performed. The required DOTA solutions (1-500 pmol DOTA) were obtained by dilution of the initial 1 mM DOTA solution (CheMatech, France) with 0.5 M sodium acetate (pH 4.5). The prepared DOTA dilutions were mixed with 2.5-4 MBq 161 Tb (corresponding to 3.1-5 pmol), Gracheva et 
land bv, the Netherlands) at different DOTA-to-nuclide molar ratios (160:1 to 1:1). The reaction solutions were incubated for 20 min at 95°C and 2 μL of each solution were deposited on TLC silica gel 60 F 254 plates, which served as a stationary phase. The mixture of 10% ammonium acetate (Sigma-Aldrich, USA) and methanol (Merck, Germany) was used as mobile phase (ratio 1:1 (v/v), pH 5.5). After elution, the phosphor screen (Multisensitive, Perkin Elmer Inc., USA) was illuminated with the TLC plate and analyzed with a Cyclon Phosphor Imager (Perkin Elmer Inc., USA Tb activity in total) was performed as described above, in the absence or in the presence of L-ascorbic acid (2.9 mg, SigmaAldrich, USA). The radiolabeling yield was determined by means of HPLC (as described above) immediately after the preparation of 161 Tb/ 177 Lu-DOTATOC. The radioactivity concentration of the labeling solutions was adjusted to 250 MBq/500 μL with saline and radiolytic stability of the radioligand was determined over time (1 h, 4 h and 24 h) by means of HPLC. Table 2 ). The calculated neutron flux at the PNA irradiation position of the SINQ facility was determined experimentally to be only~50% of its originally reported value of 4 10 13 n.cm
Results

Tb production yield (theoretical versus experimental)
.s − 1 (Table 1) , which resulted in 6-9 GBq 161 Tb after 3 weeks irradiation of the enriched 160 Gd(NO 3 ) 3 target material (Table 2 ). This was due to the fact that the spallation target had recently been replaced and was being operated at a lower beam current (1.3 mA protons instead of 2.3 mA) than normally specified (Table 1) .
Radiochemical separation of 161 Tb from the target material and accumulated impurities
By performing bench experiments using Sykam cation exchange resin column (10 mm × 170 mm) and long-lived radioactive tracers, conditions for the efficient separation of Tb from up to 140 mg of Gd 2 O 3 and the presence of various impurities were established (Additional file 1: Figure S1 and S2). Subsequently, the established experimental conditions (Sykam resin; 0.13 M α-HIBA, pH 4.5; 0.6 mL/min eluent flow rate) were applied towards the purification of the reactor-produced Tb separation from Gd target material and the impurities using the Sykam resin column (Fig. 1) . 161 Tb was eluted from the Sykam resin with 20 mL α-HIBA, followed by the concentration of the radionuclide on the LN3 resin column (Additional file 1: Figure S3 ). LN3 extraction resin was reported to have low affinity for Tb ions in low concentrated acids (McAlister 2007) , thereby, allowing 161 Tb to be eluted in a small volume of 0.05 M HCl.
Based on the developed two-column purification method (combination of Sykam and LN3 resin columns), a 161 Tb purification module was designed (Fig. 2) . The module was constructed and placed inside the hot cell, making it possible to perform separations with higher activities (up to 20 GBq) of the reactor-produced 161 Tb.
The established procedure for the 161 Tb purification process using the designed module resulted in the elution of the final product ( 161 TbCl 3 ) in a small volume (500 μL) of 0.05 M HCl, with an activity concentration of 11-21 MBq/μL. A separation yield of 80-90% was achieved at EOS. Losses of 10-20% of 161 Tb activity were observed in the target dissolving, column loading and final elution steps.
Characteristics of the 161 TbCl 3 product
161 Tb, obtained after the purification process, was characterized to provide a product specification ( Table 3 ). The identification of the product was confirmed by the 161 Tb-characteristic γ-lines (Fig. 3) . The content of long-lived Tb activity at EOS (Additional file 1: Figure S4 ). The radiochemical purity of the 161 TbCl 3 , determined using radio-TLC, was > 99% (Additional file 1: Figure  S5 ). The radiolabeling yield of 161 Tb-DOTANOC showed ≥99% efficiency at 180 MBq/ nmol molar activity, which corresponds to 1-to-4 nuclide-to-peptide molar ratio (Fig. 4) . Lu (either carrier-added or no-carrier-added) was performed at different DOTA-to-nuclide molar ratios in order to monitor the quality change of the radiolanthanides of interest over a two-week period Lu (no-carrier-added) at 15:1 and 13:1 DOTA-to-nuclide molar ratios, respectively, with > 90% radiolabeling yield at Day 14 after EOS (Fig. 5 a, b) . This indicates the possibility of using the prospective drug product (e.g. DOTA peptides radiolabeled with 161 Tb) for up to 2 weeks after the chemical separation. With carrier-added 177 Lu, 90% radiolabeling yield was only achieved when using a much higher DOTA-to-nuclide radio (32:1) at the two-week time point (Fig. 5c) .
Comparison of the
The average DOTA-to-nuclide molar ratios corresponding to 50% labeling efficiency of DOTA with 161 Tb and 177 Lu were determined at specific time points (Day 3, Day 7, Day 10 and Day 14 - Table 4 ) (Additional file 1: Figure S7) . The values allow an estimation of the (Fukuda 2018; Kalekar 2017) . The pressure change due to the water evaporation and release of the gases at higher temperatures inside the ampoule may result in the ampoule cracking. The use of oxide targets (melting point 2420°C) eliminates the potential issues described and will potentially give rise to large-scale 161 Tb production in future (TBq activity). The ChainSolver code allows for quick calculations of the required masses of 160 Gd targets for the production of the desired 161 Tb activity, based on irradiation times and neutron fluxes, obtained with 59 Co monitors.
Another big advantage of the newly-devised method over that of the previouslydeveloped one is that the 161 Tb product is eluted from LN3 in a small volume and can be used directly for labeling, while the previous method required the use of evaporation after elution from AG50W-X8, thereby, increasing the risk of introduction of environmental contamination and reducing the quality of the final product. The use of LN3 also ensures elution of elements in reverse order when compared to the Sykam/α-HIBA system, therefore, any impurities that may have eluted with 161 Tb before introduction to the second column will be eluted differently from the LN3 resin column. Recently, Brezovcsik et al. reported a Tb separation procedure from massive Gd targets (> 100 mg) using a 20 cm long analytical HPLC column (GE), indicating no mass influence of Gd on the separation process (Brezovcsik 2018) . The efficiency of Tb separation from Gd was only 85%, however, showing significant overlapping of Tb and Gd peaks, which would result in the presence of "cold" Gd in the Tb final product and significantly decrease radiolabeling efficiency. The purification method described in this work provides an effective 161 Tb separation from the Gd 2 O 3 target material of masses up to 140 mg. This is a valuable result for possible future commercial application of the developed method for Tb from potential impurities present in the system, based on the combination of Sykam and LN3 resin columns.
The two-column 161 Tb purification process proposed by Lehenberger et al. (Lehenberger 2011) was adopted as the baseline for this study towards further development. The cation exchange resin of the first column, column dimension and pump flow rate were changed, while the concentration and pH of the eluent remained the same (0.13 M α-HIBA pH 4.5). The resin used for the second column was changed from AG 50 W-X8 (cation exchange resin) to LN3 (extraction resin). These modifications mentioned above played a vital role in obtaining the final product ( Tb (this work) at 1-to-4 nuclide-topeptide molar ratio (Fig. 4) immediately after the purification process with > 99% radiolabeling yield. Quantitative formation of 161 Tb-DOTATATE was possible only at 1-to-12 nuclide-to-peptide molar ratio (Lehenberger 2011).
As expected, the radiolabeling capability of the produced, no-carrier-added 161 Tb was higher than the radiolabeling capability of carrier-added Tb with DOTA was possible at Day 14 (after radiochemical separation) at 1-to-15 nuclide-to-peptide molar ratio (corresponding to 48 MBq/nmol molar activity), with > 90% radiolabeling yield (Fig. 5) . This ratio would be appropriate when using DOTA-functionalized targeting agents, such as peptides for peptide receptor radionuclide therapy (Dash 2015) . These excellent achievements indicate the possible clinical use of 161 TbCl 3 for a period of up to 2 weeks after EOS. Moreover, clinicallyapplied DOTATOC radiolabeled with 161 Tb was stable over 24 h at high radioactivity concentration, indicating that conversion and Auger electrons had no negative influence on the stability, hence, storage and transportation of 161 Tb-labeled somatostatin analogues would be feasible, as is the case for their 177 Lu-labeled counterparts.
Conclusions
A new method to separate 161 Tb from its enriched 160 Gd 2 O 3 target material and coproduced impurities was developed with the use of cation exchange and extraction chromatography, respectively. The method resulted in radionuclidically and radiochemically pure product ( Tb is suitable for high-specific radiolabeling, potentially useful for the GMP production of radioligands towards future clinical application.
